Clinical Trial Update: Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 dose adjustment trial of SK-1403 in hemodialysis patients with secondary hyperparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• SK-1403

Snippet

Sponsor: Sanwa Kagaku Kenkyusho Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED